Richard Hernandez
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Microtubule and mitosis dynamics, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Synthesis and SAR of [1,2,4]Triazolo[1,5-a]pyrimidines, a Class of Anticancer Agents with a Unique Mechanism of Tubulin Inhibition(2006)209 cited
- HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.(2003)
- → TTI-237: A Novel Microtubule-Active Compound with In vivo Antitumor Activity(2008)81 cited
- → 2-Cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization(2007)59 cited
- → The interaction of PKN3 with RhoC promotes malignant growth(2011)49 cited
- → Synthesis and Biological Activity of Analogues of the Antimicrotubule AgentN,β,β-Trimethyl-l-phenylalanyl-N-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]-N1,3-dimethyl-l-valinamide (HTI-286)(2004)49 cited
- → Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents(2008)31 cited
- → Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment(2004)26 cited
- → The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties(2009)25 cited
- → Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.(2021)15 cited